Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.31 |
| ▸ | SCN1A | P35498 | 1/20 | 0.30 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.30 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17157125 | 1.00 | APLNR (0.40) | APLNRKMT2AGRM2GRM3ALDH1A1 | |
| SCHEMBL24938563 | 0.79 | TSHR (0.30) | — | |
| SCHEMBL15007599 | 0.79 | APLNR (0.43) | APLNRKMT2AGRM2GRM3 | |
| SCHEMBL15007598 | 0.79 | APLNR (0.43) | APLNRKMT2AGRM2GRM3 | |
| SCHEMBL16489099 | 0.78 | GRM2 (0.31) | APLNRGRM2GRM3OPRM1OPRD1 | |
| SCHEMBL17171344 | 0.77 | ATM (0.42) | APLNRKMT2AGRM2GRM3 | |
| SCHEMBL18084402 | 0.74 | APLNR (0.35) | APLNRKMT2A | |
| SCHEMBL27641429 | 0.73 | — | — | |
| SCHEMBL15851446 | 0.71 | GRM2 (0.37) | APLNRKMT2AGRM2GRM3 | |
| SCHEMBL15851447 | 0.71 | GRM2 (0.37) | APLNRKMT2AGRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10159745-B2 | Tubulysin derivatives | MEDIMMUNE, LLC (US) | 2018-12-25 | — | — | US | disclosed |
| EP-3129362-A1 | TUBULYSIN DERIVATIVES | Medimmune, LLC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20160339114-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160339114-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160339114-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2016-11-24 | — | — | US | disclosed |
| US-9427479-B2 | Tubulysin derivatives | MEDIMMUNE LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-9427479-B2 | Tubulysin derivatives | MEDIMMUNE LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-9427479-B2 | Tubulysin derivatives | MEDIMMUNE LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2015-10-15 | — | — | US | disclosed |
| WO-2015157594-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2015-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10159745-B2 | Tubulysin derivatives | TEKT1, TWF2, TEK | APLNR 1304/4885KMT2A 2974/4885GRM2 4329/4885 |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | TEKT1, TWF2, TEK | APLNR 1304/4885KMT2A 2974/4885GRM2 4329/4885 |
| US-20160339114-A1 | TUBULYSIN DERIVATIVES | TEKT1, TWF2, TEK | APLNR 1304/4885KMT2A 2974/4885GRM2 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.